Ausgewählte Publikationen NZM

  1. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.
    van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller P, Szafrańska AK, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Rüegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Höller C, Debast SB, Wolfhagen MJ, Hopman J, Kluytmans J, Langelaar M, Notermans DW, ten Oever J, van den Barselaar P, Vonk AB, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith G, Zambon M, Serr A, Götting T, Ebner W, Thürmer A, Utpatel C, Spröer C, Bunk B, Nübel U, Bloemberg GV, Böttger EC, Niemann S, Wagner D, Sax H (2017)
    Lancet Infect Dis 17: 1033-1041
  2. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.
    Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P (2017)
    J Antimicrob Chemother 72: 376-384
  3. Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes.
    Rominski A, Selchow P, Becker K, Brülle JK, Dal Molin M, Sander P (2017)
    J Antimicrob Chemother 72: 2191-2200
  4. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.
    Schön T, Miotto P, Köser CU, Viveiros M, Böttger EC, Cambau E (2017)
    Clin Microbiol Infect 23: 154-160
  5. Non-mutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase.
    Freihofer P, Akbergenov R, Teo Y, Juskeviciene R, Anderson DI, Böttger EC (2016)
    RNA 22: 1836-1843
  6. Standard genotyping overestimates transmission of Mycobacterium tuberculosis among immigrants in a low-incidence country.
    Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens JP, Calmy A, Mazza Stalder J, Jaton K, Rieder HL, Pfyffer GE, Siegrist HH, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger EC, Gagneux S, Fenner L (2016)
    J Clin Microbiol 54: 1862-1870
  7. Diagnostic molecular mycobacteriology in regions with low tuberculosis endemicity: combining real-time PCR assays for detection of multiple mycobacterial pathogens with line probe assays for identification of resistance mutations.
    Deggim-Messmer V, Bloemberg GV, Ritter C, Voit A, Hömke R, Keller PM, Böttger EC (2016)
    EBioMedicine 9: 228-237
  8. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus Statement.
    Dominguez J, Böttger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R,Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C (2016)
    Int J Tuberc Lung Dis 20: 24-42
  9. Mycobacterium tuberculosis drug resistance testing: challenges, recent developments and perspectives.
    Schön T, Miotto P, Köser CU, Viveiros M, Böttger EC, Cambau E (2016)
    Clin Microbiol Infect 23: 154-160
  10. Revisiting susceptibility testing in multidrug resistant tuberculosis by a standardized quantitative phenotypic assessment in a European multicenter study.
    Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, Mattys V, Hoffner S, Richter E, Perez-del-Molino L, Cirillo D, van Soolingen D, Böttger EC (2015)
    J Antimicrob Chemother 70: 686-696
  11. A mutation associated with clofazimine and bedaquiline cross-resistance in MDRTB following bedaquiline treatment.
    Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC (2015)
    Eur Respir J 45: 554-557
  12. Aminoglycoside modifying enzymes determine the innate susceptibility to aminoglycoside antibiotics in rapidly growing mycobacteria.
    Maurer F, Bruderer V, Castelberg C, Ritter C, Scherbakov D, Bloemberg G, Böttger E (2015)
    J Antimicrob Chemother 70: 1412-1419
  13. Prolonged outbreak of Mycobacterium chimaera infection after open chest heart surgery.
    Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rössle M, Falk V, Kuster SP, Böttger EC, Weber R (2015)
    Clin Infect Dis 61: 67-75
  14. Determination of MIC distribution and epidemiological cut-off values for bedaquiline and delamanid in Mycobacterium tuberculosis using MGIT 960/ TB eXiST.
    Keller P, Hömke R, Ritter C, Valsesia G, Bloemberg GV, Böttger EC (2015)
    Antimicrob Agents Chemother 59: 4352-4355
  15. Health-care associated prosthetic heart valve, aortic vascular graft, and disseminated Mycobacterium chimaera infections subsequent to open heart surgery.
    Kohler P, Kuster SP, Bloemberg GV, Schulthess B, Frank M, Tanner FC, Rössle M, Böni C, Falk V, Wilhelm MJ, Sommerstein R, Achermann Y, ten Oever J, Debast SB, Wolfhagen MJHM, Brandon Bravo Bruinsma GJ, Vos MC, Bogers A, Serr A, Beyersdorf F, Sax H, Böttger EC, Weber R, van Ingen J, Wagner D, Hasse B (2015)
    Eur Heart J 36: 2745-2753
  16. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis.
    Bloemberg GV, Keller P, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla N, Rothe T, Hömke R, Ritter C, Feldmann J, Schulthess B, Gagneux S, Böttger EC (2015)
    N Engl J Med 373: 1986-1988
  17. Evaluation of the AID TB Resistance line probe assay for rapid detection of genetic alterations associated with Mycobacterium tuberculosis drug resistance.
    Ritter C, Lucke K, Sirgel FA, Warren RW, van Helden PD, Böttger EC, Bloemberg GV (2014)
    J Clin Microbiol 52: 940-946
  18. Transmission of multidrug-resistant tuberculosis in low-incidence setting, Switzerland, 2006 to 2012.
    Somoskovi A, Helbling P, Deggim V, Hömke R, Ritter C, Böttger EC (2014)
    Euro Surveill 19: pii=20736
  19. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
    Maurer F, Castelberg C, Quiblier C, Böttger E, Somoskövi A (2014)
    J Antimicrob Chemother 69: 1559-1563
  20. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus.
    Maurer F, Bruderer V, Ritter C, Castelberg C, Bloemberg GV, Böttger EC (2014)
    Antimicrob Agents Chemother 58: 3828-3836
  21. Postsurgical wound infections due to rapidly growing myciobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014.
    Maurer FP, Castelberg C, von Braun A, Wolfensberger A, Bloemberg GV, Böttger EC, Somoskovi A (2014)
    Euro Surveill 19: pii=20905
  22. High level resistance to isoniazid and ethionamide in multidrug resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.
    Machado D, Perdigao J, Ramos J, Couto I, Portugal I, Ritter C, Böttger EC, Viveiros M (2013)
    J Antimicrob Chemother 68: 1728-1732
  23. Prosthetic valve endocarditis and bloodstream infection due to Mycobacterium chimaera.
    Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, Bloemberg G, Hombach M, Hasse B (2013)
    J Clin Microbiol 51: 1769-1773
  24. Evaluation of Cobas TaqMan MTB for direct detection of the Mycobacterium tuberculosis complex in comparison with Cobas Amplicor MTB.
    Bloemberg GV, Voit A, Ritter C, Deggim V, Böttger EC (2013)
    J Clin Microbiol 51: 2112-2117
  25. Integrating the Xpert MTB/RIF assay into a diagnostic workflow for rapid detection of Mycobacterium tuberculosis in a low-prevalence area.
    Deggim V, Somoskövi A, Voit A, Böttger EC, Bloemberg GV (2013)
    J Clin Microbiol 51: 2396-2399
  26. HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.
    Fenner L, Egger M, Bodmer T, Furrer H, Ballif M, Battegay M, Helbling P, Fehr J, Gsponer T, Rieder HL, Zwahlen M, Hoffmann M, Bernasconi E, Cavassini M, Calmy A, Dolina M, Frei R, Janssens JP, Borrell S, Stucki D, Schrenzel J, Bötter EC, Gagneux S (2013)
    PLoS Genet 9: e1003318
  27. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.
    Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD (2013)
    PLoS One 8: e59414
  28. Transmission of M abscessus in patients with cystic fibrosis.
    Böttger EC (2013)
    Lancet 382: 503-504
  29. Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41) methylase.
    Maurer F, Rüegger V, Ritter C, Bloemberg GV, Böttger EC (2012)
    J Antimicrob Chemother 67: 2606-2611
  30. Mycobacterium tuberculosis population structure determines the outcome of genetic based second-line drug resistance testing.
    Streicher E, Bergval I, Dheda K, Böttger EC, Gey van Pitius N, Bosman M, Coetzee G, Anthony R, van Helden PD, Victor TC, Warren RM (2012)
    Antimicrob Agents Chemother 56: 2420-2427
  31. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis.
    Fenner L, Egger M, Bodmer T, Altpeter E, Zwahlen M, Jaton K, Pfyffer GE, Borrell S, Dubuis O, Bruderer T, Siegrist HH, Furrer H, Calmy A, Fehr J, Stalder JM, Ninen B, Böttger EC, Gagneux S (2012)
    Antimicrob Agents Chemother 56: 3047-3053
  32. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC (2012)
    J Antimicrob Chemother 67: 1088-1093
  33. Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis.
    Sirgel FA, Tait M, Warren RM, Streicher EM, Böttger EC, van Helden PD, Gey van Pittius NC, Coetzee G, Hoosain EY, Chabula-Nxiweni M, Hayes C, Victor TC, Trollip A (2012)
    Microb Drug Resist 18: 193-197